These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19317948)

  • 1. ISA247: quality of life results from a phase II, randomized, placebo-controlled study.
    Gupta AK; Langley RG; Lynde C; Barber K; Gulliver W; Lauzon G; Aspeslet LJ; Foster RT; Huizinga RB; Yatscoff RW
    J Cutan Med Surg; 2008; 12(6):268-75. PubMed ID: 19317948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.
    Bissonnette R; Papp K; Poulin Y; Lauzon G; Aspeslet L; Huizinga R; Mayo P; Foster RT; Yatscoff RW; Maksymowych WP;
    J Am Acad Dermatol; 2006 Mar; 54(3):472-8. PubMed ID: 16488299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.
    Papp K; Bissonnette R; Rosoph L; Wasel N; Lynde CW; Searles G; Shear NH; Huizinga RB; Maksymowych WP
    Lancet; 2008 Apr; 371(9621):1337-42. PubMed ID: 18424323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.
    Ellis CN; Mordin MM; Adler EY;
    Am J Clin Dermatol; 2003; 4(2):131-9. PubMed ID: 12553852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis.
    Finlay AY; Salek MS; Haney J;
    Dermatology; 2003; 206(4):307-15. PubMed ID: 12771471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study.
    Tang MM; Chang CC; Chan LC; Heng A
    Int J Dermatol; 2013 Mar; 52(3):314-22. PubMed ID: 23414155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP; Shear N; Shumack S; Henninger E;
    BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H; Nakagawa H;
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial.
    van de Kerkhof PC
    Br J Dermatol; 2004 Sep; 151(3):663-8. PubMed ID: 15377355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.
    Fernandez-Peñas P; Jones-Caballero M; Espallardo O; García-Díez A
    Br J Dermatol; 2012 Apr; 166(4):884-7. PubMed ID: 22229951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
    Salek MS; Finlay AY; Lewis JJ; Sumner MI
    Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
    J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment.
    Simpson MJ; Chow C; Morgenstern H; Luger TA; Ellis CN
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1415-20. PubMed ID: 25917214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.